ATHE News | Roxom Stocks

1 BTC

- USD

Loading market data...

Mkt Cap

$47.5M

Volume

55.88K

Mkt Cap

$47.7M

Volume

55.88K

Next Earnings

N/A

Chart Earnings News About Insider Filings

Multiple System Atrophy Clinical Trial Pipeline Gains Momentum: 22+ Companies Lead the Charge in Pioneering New Treatments | DelveInsightThe multiple system atrophy (MSA) clinical trial pipeline is experiencing significant momentum with 22+ companies developing 24+ pipeline drugs. The pipeline is diversifying beyond traditional approaches to include oral small molecules, cell replacement therapies, gene therapies, and next-generation alpha-synuclein inhibitors. Recent developments include Alterity Therapeutics achieving FDA alignment on Phase III for ATH434, Teva receiving Fast Track designation for TEV-56286, and iRegene Therapeutics enrolling the first patient in a randomized controlled trial for NouvNeu004 in China.GlobeNewswire Inc. · Aug 26, 2026

Alpha-Synuclein Inhibitors Clinical Trial Pipeline as Novel and Extensive 22+ Therapies Likely to Enter in the Domain | DelveInsightThe article discusses the growing pipeline of alpha-synuclein inhibitors, a class of investigational therapies targeting the aggregation of alpha-synuclein, a protein implicated in neurodegenerative diseases. The pipeline includes over 20 active players and 22+ pipeline therapies, with several promising candidates in various stages of clinical trials.GlobeNewswire Inc. · Feb 13, 2025

Tau Inhibitors Clinical Trial Pipeline Analysis Demonstrates 25+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsightThe rising incidence of Alzheimer's and other tau-related disorders is driving the demand for tau-targeting therapies. Innovative approaches, particularly small molecules that inhibit tau aggregation, are at the forefront of R&D. Increased funding is accelerating advancements in neurodegenerative disease treatments, positioning tau inhibitors as a key market driver.GlobeNewswire Inc. · Oct 14, 2024

Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences’ WebinarMELBOURNE, Australia and SAN FRANCISCO, June 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer will present a company overview at the MST Access ‘Hidden Gems in Life Sciences’ webinar on Thursday, 13 June 2024 in Australia / Wednesday, 12 June 2024 in the United States.GlobeNewswire Inc. · Jun 12, 2024

Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study- New bioMUSE Data Informs ATH434-202 Study Endpoints -GlobeNewswire Inc. · May 29, 2024

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review- ATH434-201 Trial on Track to Complete in November 2024 –GlobeNewswire Inc. · May 8, 2024

Appendix 4C – Q3 FY24 Quarterly Cash Flow ReportHighlightsGlobeNewswire Inc. · Apr 30, 2024

Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s Ataxia– New Evidence Indicates ATH434 can Function as an Iron Chaperone to Redistribute Iron –GlobeNewswire Inc. · Apr 29, 2024

Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting– ATH434 Improved Motor Performance and General Function in a Primate Model of Parkinson’s Disease –GlobeNewswire Inc. · Apr 17, 2024

Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day SessionShares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities and nerve-related symptoms. Ultragenyx Pharmaceutical shares dipped 9.4% to $42.46 on Monday. Here are some other stocks moving in today's mid-day session. Gainers Soligenix, Inc. (NASDAQ: SNGX) shares surged 71.5% to $0.6679 after the company announced that it was granted orphan drug designation to the active ingredient in MarVax for the prevention and post-exposure prophylaxis against MARV infection by the FDA. Longeveron Inc. (NASDAQ: LGVN) surged 54% to $2.6350 following insider buys from multiple company executives. SuperCom Ltd. (NASDAQ: SPCB) shares gained 39.4% to $0.3849 after jumping around 18% on Friday. Piedmont Lithium Inc. (NYSE: PLL) shares gained 32.1% to $16.75 following a 5% decline on Friday. Snap One Holdings Corp. (NASDAQ: SNPO) surged 31.6% to $10.71 after the company announced that it will be acquired by Resideo Technologies. Organovo Holdings, Inc. (NASDAQ: ONVO) shares surged 30.9% to $1.32 after the company announced Phase 2 results for FXR314. Study results demonstrated statistically significant reduction in liver fat content from baseline in patients receiving FXR314 compared to placebo. Kuke Music Holding Limited (NASDAQ: KUKE) jumped 27% to $2.7650. HUB Cyber Security Ltd. (NASDAQ: HUBC) gained 24% to $1.61 after gaining over 11% on Friday. Edgio, Inc. (NASDAQ: EGIO) gained 24% to $22.18. Kaival Brands Innovations Group, Inc. (NASDAQ: KAVL) ...Benzinga · Apr 15, 2024

ATHEAlterity Therapeutics Limited American Depositary Shares

ATHE

Pay with—

Start Trading

Available Balance0.00

Your PositionYou don't own any ATHE yet.

Related Tickers

Earnings

Mkt Cap

$47.5M

Volume

55.88K